# A Trial of One-week on/One-week Off Temozolomide Versus Continuous Dose-Intense Temozolomide in Patients With Glioblastoma Multiforme at First Relapse

> **NCT02330991** · PHASE2 · COMPLETED · sponsor: **Beijing Sanbo Brain Hospital** · enrollment: 204 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT02330991
- **Lead sponsor:** Beijing Sanbo Brain Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2020-03
- **Final completion:** 2020-09
- **Target enrollment:** 204 (ACTUAL)
- **Last updated:** 2023-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02330991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02330991, "A Trial of One-week on/One-week Off Temozolomide Versus Continuous Dose-Intense Temozolomide in Patients With Glioblastoma Multiforme at First Relapse". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02330991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*